A checkup on weight-loss drugs

The U.S. threatens "economic D-Day" for Iran and its trading partners. Canada and the U.S. risk a trade war with tit-for-tat tariffs. Tesla and other automakers are recalling over 4 million vehicles in China. And how cyclosporiasis is impacting farmers, even in locations where th ...  Show more

Canada's Prime Minister Mark Carney promises "dollar for dollar" tariffs on some U.S. goods in retaliation for 50% ​levies ordered by President Donald Trump. A Chinese-made humanoid robot beats Usain Bolt's 100m world record. IndyCar’s Freedom 250 Grand Prix will zoom through Was ...  Show more

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ...  Show more

A new group of drugs for type 2 diabetes and obesity have shown to be more effective for weight loss than any previous medications. Some medications like Ozempic and Wegovy have surged in popularity thanks in part to celebrity use. But who should be taking them? And are they safe ...  Show more

Today’s podcast is about the weight-loss drug revolution—which I believe might be one of the most important stories in the world right now. Despite all the attention weight-loss drugs are receiving, it’s possible that they might soon affect the world even more than we realize as ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more